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ABSTRACT
Murine models of human multiple myeloma (MM) are key tools for the study 
of disease biology as well as for investigation and selection of novel candidate 
therapeutics for clinical translation. In the last years, a variety of pre-clinical 
models have been generated to recapitulate a wide spectrum of biological features 
of MM. These systems range from spontaneous or transgenic models of murine 
MM, to subcutaneous or orthothopic xenografts of human MM cell lines in immune 
compromised animals, to platform allowing the engraftment of primary/bone marrow-
dependent MM cells within a human bone marrow milieu to fully recapitulate human 
disease. Selecting the right model for specific pre-clinical research is essential for 
the successful completion of investigation. We here review recent and most known 
pre-clinical murine, transgenic and humanized models of MM, focusing on major 
advantages and/or weaknesses in the light of different research aims.
INTRODUCTION
Multiple myeloma (MM) is characterized by the 
expansion of malignant plasma-cells (PCs) within a 
permissive bone marrow microenvironment (BMM) 
that promotes tumor cell survival and proliferation 
[1]. A preexisting premalignant condition, known as 
monoclonal gammopathy of undetermined significance 
(MGUS), is a common step of MM development [2]. The 
transition from MGUS to MM takes place by progressive 
mutational events accompanied by changes in the BMM 
[3, 4]. MM therapy has tremendously improved in the last 
few years together with the understanding of mechanisms 
promoting the onset and development of the disease 
[5]. Most of preclinical findings in MM research that 
translated into clinics as effective therapies have been 
developed by the use of a variety of in vivo models, which 
aim to recapitulate the disease and to provide insights on 
the interactions between MM cells and the surrounding 
microenvironment. Such models represent to date the 
basic tool to investigate and predict the effectiveness of 
novel therapeutic strategies. In this work, we will review 
the most relevant in vivo experimental platforms for the 
study of MM pathogenesis and for drug discovery.
THE 5TMM MODEL: A MURINE 
BACKGROUND FOR MM 
DEVELOPMENT
Specific mouse strains may spontaneously develop 
age-associated malignancies. Among them, C57BL/
KalwRij are prone to develop B cell lymphoproliferative 
disorders, as approximately 80% of these mice carry a 
monoclonal component (MC), resembling human MGUS 
[6]. A very small fraction (0.5%) of mice progress to MM 
and Waldenstrom Macroglobulinemia. Mice spontaneously 
developing MM disease represent the original 5TMM 
model. Bone marrow (BM)-MM cells from these mice 
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can be efficiently transplanted into syngeneic mice to 
easily reproduce the disease. Indeed, from the original 
5TMM, several cell lines have been established, such 
as: 5T2 that reproduces different milestones of advanced 
disease including serum paraprotein production and 
lytic bone lesion formation; 5T33, more aggressive, 
with preferential dissemination to spleen and liver. It 
is therefore possible to derive mice carrying extensive 
or very limited skeleton damages, with malignant PC 
clones confined to the BM and spleen and with different 
growth patterns. In this model, cytogenetic abnormalities 
showed hyperdiploid features, with lower frequency of 
translocations as compared to human disease [7]. MM 
pathogenesis can be further evaluated by crossing mice 
with specific genetic backgrounds, such as recombinant 
activating gene 2 (-/-) (RAG-2 -/-) mice that lack T and B 
cell proper development [8]. These mice allow to study the 
interactions between MM cells and the surrounding BMM, 
including the immune system, and several findings such as 
the MM cells cross talk with BM stromal cells (BMSCs), 
the BM homing of malignant PCs and the overwhelming 
osteoclast (OCL) activity as the promoter of MM related 
bone disease (MMBD) are among the most relevant 
achievements of this model (Figure 1). Additionally, this 
model constitutes a suitable platform for drug discovery 
and has been largely used for in vivo evaluation of several 
new compounds, especially due to the significant number 
of animals bearing the same disease that may be easily 
produced, thus allowing the conduction of statistically 
relevant studies. However, the main limitation of this 
model resides in the exclusive murine genetic background 
that may limit the study of compounds targeting human 
specific targets.
All these points need to be considered in the 
translation process to the clinical setting.
THE XENOGRAFT MODELS: 
PLATFORMS FOR NEW DRUGS 
SCREENING
Although the 5T model has been a milestone for the 
comprehension of MM pathogenesis, several investigators 
have tried to overcome the limit of “genetically murine 
myeloma”, in the aim of testing innovative drugs 
against human MM cells and their microenvironment. 
The earliest methods attempted to engraft human MM 
cells in an animal recipient relied on the injection either 
subcutaneously (s.c.) or systemically (intravenously, i.v. or 
intraperitoneally, i.p.) of MM cell lines in SCID and NOD/
SCID mice. In these mice strains, engraftment of tumor 
cells is allowed by the lack of T and B cells (SCID and 
NOD/SCID) and reduced NK activity (NOD/SCID). The 
injection route is relevant in this system as the s.c. route 
will be followed by the growth of palpable tumors only in 
the injection site, while the systemic injection will give 
rise to disseminated involvement of different organs such 
as spleen, liver, lungs and bone marrow, depending on the 
cell line used [9–11]. In the s.c. model, the growth of MM 
cells can be easily measured by a caliper or ultrasound 
(that further allows the study of angiogenesis) until mouse 
death or sacrifice. Indeed, tumor volume and mouse 
survival are the main objective parameters to ascertain the 
effect of a specific drug. In the i.v. model, MM cell growth 
is diffuse in different organs and the burden of disease can 
be evaluated by standard imaging techniques (microCT/
MRI/PET) [10]. Alternatively, MM cells are transduced 
to express a bioluminescent or fluorescent marker, thus 
allowing the detection of tumor cells by dedicated imaging 
devices. In both routes models, it is feasible to detect 
monoclonal component (MC) in the mouse sera as well as 
other biochemical markers (e.g. beta 2 microglobulin) that 
represent an indirect measurement of the disease burden. 
Both models have been developed in the aim to investigate 
new drugs and still represent the most common methods to 
study innovative drugs activity in vivo [12, 13].
The s.c. model has the advantage that the tumor 
can be easily monitored and measured during treatments. 
However, s.c. growth does not recapitulate the human 
disease due to several limitations. Specifically, in this 
model, MM cells proliferate in the absence of the 
peculiar BMM that sustains the expansion of malignant 
PCs and drives the development of bone damage and 
drug resistance. Additionally, MM cell lines used for 
engraftment are mainly derived from extramedullary sites 
such as pleural effusions or peripheral blood of advanced 
MM patients. These cells have lost the dependence 
from the BMM and have changed significantly their 
genetic background to a late stage disease- instead of 
intramedullary MM- type.
When considering the i.v. route, homing to the BM is 
also found, according to the specific type of MM cell line 
used. In these cases, the murine BM can be infiltrated with 
consequent bone damage as in the human MM. However, 
along the course of the disease, other mice organs host 
MM cells, reproducing an in vivo scenario commonly not 
observed in human disease. Thus, both models are very 
useful and easy-to-handle to quickly assess the activity 
of new cytotoxic drugs, but do not provide insights on 
the critical interactions between malignant PCs and their 
own BMM. This information is presently somewhat 
relevant to allow a successful translation in clinics of 
innovative drugs with selective mechanisms of action 
that in most cases involves the BMM. To overcome the 
relevant limitations of previous models, some attempts 
to develop new “humanized” models have been designed 
and made available (Figure 2). In these models, the basic 
idea is to reproduce the human BMM by implanting bone 
recipients in the flank of mice and then seeding them 
with fresh primary BM explanted cells or IL-6-dependent 
MM cell lines. The advantage of this approach is that 
MM cells grow in an orthotopic full human environment, 
where BMSCs support MM cell proliferation that in turn 
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triggers osteoclasts (OCL) activity and suppresses bone 
apposition, thus reproducing the development of BD as 
observed in patients. Several variants of this model have 
been developed according to the type of the bone chip 
used (Figure 2).
The SCID-hu model
In the SCID-hu model, a human fetal bone chip 
(FBC) is implanted in the recipient mouse. In this model 
[14], MM cell lines home exclusively to the human 
implant instead of murine bone. Furthermore, when a 
contralateral FBC was implanted, MM cells migrated 
from the previously injected FBC to the contralateral 
one, while sparing the murine bone and obviously 
all other murine normal tissues. Engrafted MM cells 
produced MC and IL-6, which correlated with the time 
from implantation and the tumor burden. Following this 
initial experience, primary PCs from MM patients were 
successfully engrafted into SCID-hu models [15]. MC 
was detected in mouse sera, while human bone sections 
showed increased OCL activity and neo-angiogenesis, 
resembling human disease (Figure 3). The FBC has 
been also demonstrated to be an excellent recipient 
for engraftment of IL-6 dependent MM cells (INA-6) 
[16]. These cells, in fact, are fully dependent on human 
BMSCs and/or human IL-6, which is a well recognized 
key factor and target for MM [17–28], and cannot be 
used for production of conventional s.c. xenografts since 
do not grow under murine IL-6 stimulation. On the other 
side, administration of human IL-6 induces mice cachexia 
and therefore these cells cannot be used in vivo without 
a recipient recapitulating the human bone milieu. In this 
model, extensive BM infiltration by INA-6 was paralleled 
by an increased beta 2 microglobulin in mice sera. The 
advantages of using the INA-6 implanted SCID-hu model 
are the unlimited high reproducibility of the data with 
a cell line that recapitulates more accurately the human 
disease, growing in an orthotopic environment. The 
latter is a crucial issue to study mechanistic pathways of 
myeloma-genesis and to ascertain the effects of new drugs 
against MM cells and BMM [16, 23, 26, 29–33].
Indeed, the use of these models allowed investigators 
to define the role of key signaling pathways or to 
Figure 1: 5TMM and TG mouse models of MM. The pictures illustrate different strategies adopted to recapitulate MM disease. 
Models are divided according to their main characteristics: the green quadrant includes models of spontaneous mouse model of MM; the 
blue quadrant includes models of transgenic murine MM; each quadrant is accompanied by a table briefly describing the most relevant 
advantages and limits of each model. BD: bone disease; MM: multiple myeloma; BMM: bone marrow microenvironment
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investigate several new agents. For example, p38 mitogen 
activated kinase (MAPK) is constitutively activated in 
MM and contributes to tumor growth [34]. Abrogation of 
p38 signaling within MM cells attenuates OCL activity and 
restores bone apposition in a SCID-hu environment. The 
same model allowed demonstration of the anti-MM effects 
of thalidomide in vivo [35]. The potency of the model to 
study new drugs has been further tested by Tai et al., who 
showed that targeting Bruton tyrosine kinase (BTK) in 
MM cells and OCLs impairs MM growth and attenuates 
MMBD [38]. MM-dependent OCL activity is clearly 
reproducible in the SCID-hu model, where zoledronic 
acid, the most common bisphosphonate routinely used 
for MM supportive therapy, efficiently attenuates bone 
damage [35]. Osteoblasts (OBL) suppression and aberrant 
OBL/OCL crosstalk through Ephrin B2/B4 (EPHB2/B4) 
interaction has been also described within FBC [36]. The 
authors demonstrated that interfering with the EPH axis by 
EPH B2/B4 -FC molecules determined reversal of OBL 
suppression and reduced OCL levels in myeloma carrying 
SCID-hu mice.
Even if the SCID-hu model proved to be effective 
in studying MM pathogenesis as well as other plasma 
cell discrasias such as Waldenstrom’s macroglobulinemia 
[37–39] and the activity of novel drugs, its major 
limitations rely on FBC availability for many institutions. 
Furthermore, fetal BMM does not exactly recapitulate 
adult BMM. Alternative methods have been developed in 
the aim to overcome these issues.
The SCID-rab model
In the SCID-rab model human fetal bone chips are 
replaced by rabbit bones. MM cells engraft into the rabbit 
bone reproducing the human disease [40]. The SCID-
rab model has been the backbone for studying the bone-
building effects of proteasome inhibitor (PI) bortezomib, 
which are independent from anti-neoplastic effects of the 
PI. Indeed, when mice are exposed to PI, bone mineral 
density (BMD) increases in both myelomatous and 
non-myelomatous bones. These data represented the 
basis to further explore bone building activity of novel 
Figure 2: Xenograft and SCID models of MM. The pictures illustrate different strategies to recapitulate human MM disease in 
mice. The yellow quadrant includes models where human MM cells are grown in murine bone marrow microenvironment; the red quadrant 
includes models where human MM cells are grown in human autologous or allogenic bone marrow microenvironment; each quadrant 
is accompanied by a table briefly describing the most relevant advantages and limits of each model. BD: bone disease; MM: multiple 
myeloma; BMM: bone marrow microenvironment
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drugs within SCID-rab. In this model, [41] the effects 
of anti-DKK-1 mAb that was able to increase BMD in 
the presence of patient derived malignant PCs, has been 
evaluated. DKK-1 negatively regulates WNT signaling 
and OBL differentiation. By neutralizing DKK-1, OBL 
numbers were restored, while OCLs were significantly 
reduced. These findings were confirmed and implemented 
by testing a clinical grade anti DKK-1 Ab in the SCID-
hu model [30], thus demonstrating the close relationship 
between the two models.
The SCID-rab model is a suitable model for 
preclinical investigation in MM, but it certainly retains 
its own limits as rabbit bone, although ontogenetically 
related, cannot be strictly compared to human bone. 
However, the development of bone chip based models 
unveiled the potentialities of this approach and prompted 
investigators to ameliorate this system.
The SCID-synth-hu model
In an effort to reproduce human MM 
microenvironment in the mouse, synthetic scaffolds, 
closely resembling the trabecular structure of human 
bone were developed. A relevant option has been 
provided with the generation of the SCID-synth-hu model 
(Figure 2) [42]. It is based on a three-dimensional poly-
ε-caprolactone polymeric scaffold (PS), featuring the 
human trabeculae, wherein MM cells/primary PCs and 
BMSCs can be successfully loaded. The PS is either 
cultured in vitro or implanted in the mouse flank as for 
FBC/rabbit chip. In this latter case, the recipient was then 
engrafted with cell populations from whole bone marrow 
aspirates directly in vivo. Treatment with i.p. bortezomib/
dexametasone regimen led to dramatic decrease of MC 
in the mouse sera and clearance of MM cells within the 
retrieved scaffold. An intriguing preliminary finding 
was also the development of neo-angiogenesis in the 
MM coated PS [42]. Following-up this observation, Zhu 
et al. [43] demonstrated that bone marrow endothelial 
cells (BMECs) support MM cell growth, migration and 
BM homing within PS either in vitro and implanted 
in the mice. BMECs-MM cells interaction is mainly 
dependent on CD147, which is highly expressed by MM 
cells as compared to normal PCs and binds cyclophilin 
A (cyPA). cyPA is secreted by BMECs. CD147 blockade 
exerted potent anti MM activity as shown in the PS MM 
model. These data demonstrated that the PS is a powerful 
platform to recapitulate MM disease and to test a variety 
of innovative therapeutic approaches [29, 33, 42, 44–46]. 
Figure 2 summarizes the main characteristics of the most 
important models discussed in this section.
SPECIAL CONSIDERATION ON THE USE 
OF NOD SCID GAMMA NULL MOUSE AS 
XENOGRAFT MODEL OF MM
The recently introduced NOD/SCID gamma null 
(NSG) mouse strain lacks IL-2 gamma chain, resulting 
in the absence of B/T/NK activity and severe impairment 
of antigen presenting cells and complement [47]. Some 
authors attained successful engraftment of I.V. injected 
Figure 3: Bone-disease model. The picture shows the radiologic evidence of a bone lytic lesion within a fetal bone chip. In the cartoon 
on the left, the main actors determining the bone resorption activity are reported. Th17: T helper 17 lymphocytes; MDSC: myeloid-derived 
suppressor cell; SC: stromal cell; OBL: osteoblast; MM: multiple myeloma cell; OCL: osteoclast.
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U266 MM cells into NSG recipients following 2.4 gy 
irradiation (demonstrated to be unnecessary for tumor 
engraftment in subsequent reports) (Figure 2) [48]. U266 
showed specific homing to murine BM, which is observed 
also with other MM cells such as OPM2, JJN3 and 
RPMI8226, and in contrast to NOD/SCID IV implants [10, 
44, 49, 50]. Homing to the BM is reproducibly attained 
and classical features of MMBD can be observed with 
increased OCL activity, OBL reduction and lytic lesions 
across the skeleton [49]. However, it should be taken 
into account, that these models may present an extensive 
burden of extramedullary disease, thus mostly resembling 
very aggressive or late stage MM disease more than 
classical indolent myeloma. Again, the major limitation of 
this model is due to cell lines, that are better representative 
of a BMM-independent plasma cell leukemia than a MM.
Besides MM cells, patient derived malignant PCs 
have been engrafted into mice BM reproducing the 
human disease features. In this model, administration of 
zoledronic acid is effective in attenuating bone disease, 
while not affecting tumor burden. PIs such as carfilzomib 
dramatically reduced tumor burden and showed anabolic 
effects in MM implanted NSG mice, demonstrating that 
this model is an ideal platform for drug development 
and testing [49, 51]. A further refinement of NSG based 
MM models has been presented by others [52–54], where 
several MM cell lines, such as U266, L-363 and JJN3, 
or primary bone marrow cells from MM patients (both 
CD138 positive and negative fraction) have been directly 
implanted into NSG mice tibia (Figure 2). The advantages 
of intratibial implants are due to an accelerated and bone 
confined growth of MM, whose features are strictly related 
to the human disease. Interestingly, the disease spread 
over bone skeleton, and tumor burden could be easily 
determined by bioluminescent techniques in the presence 
of luminescent dye tagged MM cells and/or by MRI.
TRANSGENIC MODELS
IL-6 transgenic models
Early studies demonstrated that IL-6 is essential for 
MM cell growth in vitro and in vivo [55, 56], suggesting 
that this cytokine is the main supportive factor in mineral 
oil induced plasmacytomas (MOPCs) [57], which develop 
within the peritoneal cavity following the generation of 
inflammatory dependent granulomas [58]. Based on these 
premises, an IL-6 transgene (Tg) driven by the promoter of 
Ld gene of the major histocompatibility complex (H2-Ld) 
was generated in B6 mice and showed the development 
of massive policlonal plasmacytomas. These tumors were 
transplanted in mineral oil treated BALB/c mice, where 
MC component of IgA isotype and clonal plasmacytomas 
were observed. These plasmacytomas carried t(12;15) 
and c-myc gene rearrangements. Interestingly, when IL-6 
Tg is stabilized in BALB/c background mice through 
progressive backcrossing until N20, derived c.IL6 mice 
spontaneously developed monoclonal plasmacytomas or 
B cell lymphomas within lymphoid tissues. These tumors 
could be transplanted in mineral oil treated mice arising 
t(12;15)+ plasmacytomas [59]. These early studies were 
of relevance as they began to unveil the role of IL-6 
dependence in MM growth and the importance of tumor 
microenvironment in promoting MM development  in 
vivo. C.H2-Ld-IL6 model is still the best reference model 
to study the pathophysiology of IL-6 in MM [60]. Further 
evidence of potential microenvironment dependence of 
MOPC tumors is provided by the derived MOPC315.BM 
cell line, which is obtained by consecutive i.v. passages 
of an established MOPC315 MM. Interestingly, these 
tumors shift from a s.c. growth form to BM selective 
expansion with extensive osteolytic disease and limited 
extramedullary involvement, resembling human MM [7].
The v-ABL model
c-myc rearrangement in IL-6 driven plasmacytomas 
was not an isolated finding in early transgenic studies of 
MM. In the Eμ-v-abl model [61], the v-abl gene, which 
encodes for a constitutively active non-receptor tyrosine 
kinase, is juxtaposed with an IgH enhancer. The resulting 
Eμ-v-abl strongly promotes plasmacytoma development 
even in mineral oil free mice. In most cases a t(12;15) 
or other myc gene rearrangements could be identified, 
while double Tg Eμ-myc and Eμ-v-abl presented with 
an accelerated plasmacytoma onset (5-8 wks for double 
Tg as compared to 11-52 in Eμ-v-abl), thus confirming 
the putative role of c-MYC in MM pathophysiology. 
Acceleration of plasmacytoma onset can be attained by 
crossing the Eμ-v-abl mice with either Bim-/-, BCL2 or 
MCL-1 Tg mice [62]. The lack of pro- apoptotic signals 
or the enriched survival signals carried by crossed 
Tg facilitated MYC driven plasmacytoma-genesis by 
increasing PC frequency in normal mice and increased 
cyclin D expression. The synergistic effects of MYC and 
abl can be due to the activation of relevant pro-survival 
and proliferation signaling pathways such as RAS and 
PI3K dependent pathways. This synergy seems to be 
selective for tumorigenesis in PC lineage rather than 
lymphocytes, although the mechanisms of such selectivity 
remain not clarified.
The Vk*MYC model
In the mineral oil/transgene induced plasmacytomas 
discussed so far, tumors develop in the peritoneum, 
lymphnodes, spleen and more rarely BM. Therefore, these 
models resemble at best extramedullary MM cases and 
do not recapitulate the human disease. As discussed, a 
common element of these models is the rearrangement of 
MYC gene that drives tumor onset and development. The 
Vk*MYC model [63] aims to overcome these limitations 
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and to approximate the generated mouse tumor to human 
MM (Figure 1). The Vk*MYC is structured with a V-kappa 
exon sequence splicing in frame with the human MYC 
locus. The Tg harbors a stop codon within V-kappa exon 
that generates a DGYW motif. This motif is targeted 
by somatic hyper-mutation machinery (SHM), which 
can randomly revert the stop codon and promote MYC 
expression. In this way, MYC becomes activated along 
GC reaction, preferentially affecting PC differentiation as 
light chain regulatory sequences allow for SHM activity. 
Low proliferating monoclonal PCs accumulate into 
Vk*MYC mice, along their life, within BM and secondary 
lymphoid organs, and resemble the feature of MGUS/MM. 
Antibody production is monoclonal in most cases. Bi- or 
tri-clonal paraprotein occurs to a lesser extent, indicating 
the occurrence of different clonal PCs. Clonal PCs are 
transplanted into syngenic mice recapitulating MGUS with 
corresponding MC spikes in recipient mice. The range of 
BM PC infiltration in Vk*MYC mice encompasses true 
MGUS disease up to overt MM. These mice have on 
average lower hemoglobin levels, reduced BMD and MM 
like kidney damage, thus resembling the human disease. 
The peculiarity of this model is that the tumor recapitulates 
the slow development and progression of MM with only 
1/3 of the mice that evolve towards an extramedullary 
plasmacytoma as opposite to previously discussed models. 
The “smoldering” phenotype of the model switches to 
a more aggressive disease when BM PCs are serially 
transplanted in congenic mice [64]. The Vk*MYC has been 
used to evaluate the activity of anti-MM drugs [64]. PIs and 
ImiDs and innovative drugs such as HDAC inhibitors are 
effective drugs in the model, while standard chemotherapy 
lacks relevant activity, resembling the human disease. The 
model is also suitable to study and develop novel combo 
therapies. Another peculiarity of the Vk*MYC model is the 
reproduction of the existing cross talk between clonal PCs 
and surrounding microenvironment. This distinctive feature 
proves to be very helpful to study clonal dynamics of the 
disease. As for other tumor types, the current hypothesis of 
MM onset and development is based on the existence of 
competition among different clones at diagnosis and along 
treatment, that drives towards indolent or more aggressive 
disease courses [4]. Indeed, the Vk*MYC models allows the 
study of the evolution of distinct clones in the same mouse 
along time [65]. These clones are identified after transplant 
in congenic wild type or Vk*MYC mice to evaluate 
their behavior within transplanted mice. Interestingly, 
transplanted clones can compete out the preexisting tumor 
clones within the recipient mice, coexist with them or 
even support these clones to proliferate. A similar pattern 
is observed also in Vk*MYC mice undergoing treatment 
which by itself creates clonal selection. These different 
courses resemble the human disease and can be observed 
also in MM at diagnosis and during subsequent relapses 
[4]. The model highlights the complex role of MYC in 
MM onset and development. Several findings indicate 
that MYC is involved in MGUS to MM transition [66], 
while MYC inhibitors efficiently promote MM cell death 
in vitro [67]. If we consider that MYC activation in MM is 
sustained mainly by secondary translocations not involving 
Ig Locus and can be present in the early phases of MM 
development [68], it becomes further evident the relevance 
of the Vk*MYC model to study MM pathogenesis.
The XBP-1 model
Unfolded protein response (UPR) has a recognized 
role in PC differentiation and function [69]. Among 
regulators of UPR, XBP-1 has been investigated [69–71]. 
XBP-1 is required for PC differentiation as it is rapidly 
upregulated in B cells upon PC differentiating stimuli, 
whereas mice lacking XBP-1 retain normal B cell activity 
but show very low level of antibodies in the absence of 
PC differentiation. Based on these premises, a Eμ-XBP-1 
Tg mouse, with a prominent expression of Tg product 
in lymphoid organs (spleen, lymphnodes, bone marrow 
and thymus) has been generated [72]. By 40 wks of age, 
transgenic mice developed M spike detectable in sera, 
antibody based cast nephropathy and bone marrow PC 
infiltrate <10%. At 14-24 months of age, 1/3 of mice 
developed MM, showing >10% bone marrow PCs and 
bone lytic lesions. A human MM like gene signature was 
identified in Eμ-XBP-1 mice including over-expression of 
Cyclin D1 and MAF. The Eμ-XBP-1 Tg mouse represents 
a suitable platform to study the consequences of targeting 
UPR modulators in MM. gp96 is a ER related chaperone, 
that is strictly related to XBP-1 activity and found 
upregulated in MM patients [73]. gp96 deletion within Eμ-
XBP-1 Tg mice attenuates MM disease, further linking 
UPR and MM development in this model.
The c-MAF model
c-MAF proto-oncogene is found over-expressed 
in MM in the presence of t(14;16) [74]. On this basis, 
a TG mouse carrying the Eμ-IgH-c-MAF vector that 
allowed expression of the TG in B cell lineage has been 
generated. The same group previously demonstrated 
that c-MAF upregulation in T cell compartment led to 
development of T cell lymphomas [75]. Similarly, B 
cell compartment restricted over-expression of c-MAF 
favors B cell lymphomas in aged mice (>50 weeks of 
age) with typical features: a clonal M spike with hyper-
gammaglobulinemia, increased PCs in the bone marrow 
and cast nephropathy. Interestingly, tumor cells were 
B220+CD138+CD21+CD23+IgM+IgD-, thus resembling 
a plasma-cytic or plasma-blastic lymphoma. C-MAF 
targets such as Ccnd2 and Itgb7 were consistently 
elevated as expected, while the transcription factors 
Blimp-1 and XBP-1, which control PC differentiation 
were increased. In contrast, the main negative regulator 
of PC development, PAX-5, was downregulated in these 
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mice. Overall, these data confirm the relevance of c-MAF 
in the development of PC tumors as described in MM 
patients. However, c-MAF TG mice do not recapitulate 
MM disease as the behavior of these tumors is more 
similar to PC lymphomas. Therefore, the mechanism of 
MM development in C-MAF carrying tumors must be 
further elucitated.
THE BCL-2 FAMILY PROTEINS TG 
MODELS
BCL-2 family members exert potent anti-
apoptotic activity supporting PC survival upon 
microenvironment stimuli [76]. Among them, BCL-XL 
and Bcl-B were studied in TG models of PC tumors. A 
BCL-XL TG was developed with a K chain enhancer 
(KE) and promoter (Vk21, KP) [77]. BCL-XL TG 
developed hyper-gammaglobulinemia, extramedullary 
PC foci together with a MM like cast nephropathy. 
However, no M spikes were found. When backcrossed 
with Eμ-c-MYC mouse, the double TG mice developed 
aggressive B cell tumors, with severe lymphocytosis, 
hypergammaglobulinemia and a fatal outcome by 
5.5 weeks of age. While multiple extramedullary PC 
loci are generated, BM PC counts are not increased. 
However, lytic disease is observed in the long bones 
of sacrificed mice. Genetic features of malignant PCs 
of double TG mice were analyzed in a second report 
[78], showing the presence of several translocations, 
deletions and insertions. The most frequent aberrant 
chromosomes were 12 and 16. Among dysregulated 
genes, cyclin group genes were abnormally expressed 
as compared to normal PCs.
Bcl-B is a BCL-2 family member, whose role in 
MM pathogenesis has been previously overlooked [79]. 
Indeed, Bcl-B expression is increased in MM cell lines 
and malignant PCs from patients as compared to MGUS 
and healthy subjects. TG Eμ-IgH-Bcl-B mice showed a 
significantly shorter survival as compared to WT mice. 
They developed progressive BM plasmocytosis, anemia 
and M spike in the sera. Interestingly, IgG2b was the 
only isotype expressed in TG mice, a feature unexplained 
by investigators [79]. GEP was carried out on BM PCs 
from these mice unveiling the expression of typical 
human MM associated genes, driving PC survival and 
proliferation, and triggering bone resorption [79]. BM 
PCs from TG mice were transplantable in syngeneic 
mice reproducing the disease in the recipient. BM 
plasmocytosis in TG mice was reduced by treatment with 
standard anti MM drugs (bortezomib and melphalan). 
These data indicated that TG Eμ-IgH-Bcl-B mice 
recapitulate the human MM disease more stringently 
than BCL-XL TG and can be used as a platform for 
testing new drugs.
THE “IL-6 KNOCK IN” HUMANIZED 
MOUSE MODEL
The research of mouse models that could 
recapitulate human hematopoiesis and hematological 
malignancies has followed parallel steps along the 
last 20 years. However, the experiences in SCID-
NOD/SCID environment proved to be suboptimal 
for reproducing human hematopoiesis [80]. On this 
regard, a major improvement has been achieved 
with the development of humanized mice where 
human cytokine genes were knocked in to replace the 
corresponding mouse cytokine counterpart [80, 81]. 
This approach allows human hematopoietic cell growth 
upon more physiological stimuli as the expression 
of the selected human cytokine is tissue specific and 
finely regulated as opposite to the insertion of a TG 
or the administration of an exogenous cytokine. Based 
on these premises, a Rag2-/- IL2R -/- mouse was 
generated where human genes for M-CSF, GM-CSF, 
IL-3 and TPO were knocked in the corresponding 
mouse loci. This mouse (MITRG) allowed easier 
engraftment of human hematopoietic cells derived 
from peripheral blood or BM [81] and development 
of innate immune system cells (Figure 1). The latter is 
a very relevant feature of this model as human innate 
immune system plays a prominent role in the study of 
tumor growth in the context of chronic inflammatory 
stimuli. Indeed, Das et al. [82] knocked in IL-6 human 
gene in the MITRG mouse, followed by injection of 
INA-6 MM cell line or patient derived malignant PCs 
into the bone. In this system, MM PCs nicely grew 
within mouse BM, without showing contralateral bone 
and splenic proliferation, meaning that tumor cells 
followed a growth path that was limited to the bone as 
in the human disease. Interestingly, either CD138+ or 
CD138- BM cell fraction expanded into MITGR BM. 
Tumor cell fraction obtained from grafted mice was 
able to reproduce the disease upon transplantation in 
tumor free mice. Transplanted tumor showed better 
engraftment and growth after CD3 T cell depletion 
from primary tumor to attenuate xenograft versus host 
disease. MITGR mice proved to be an ideal recipient 
to allow malignant PC proliferation from MGUS and 
smoldering MM [82]. Comparison of genomic analysis 
by whole-exome sequencing between xenograft tumor 
cells and parental MM demonstrated similar LOH and 
CNAs patterns. This finding is very relevant when we 
consider the possibility to evaluate the evolution of 
distinct sub-clones within the mouse model. Indeed, 
an ideal model should preserve the clonal distribution 
observed in the parental tumor cells derived from the 
patient. However, even in this model, genomic changes 
could be detected in the xenografted tumors. As authors 
argued, the changes were likely due to the emergence 
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of minor sub-clonal fractions that take a proliferation 
advantage in the xenograft BM microenvironment [82]. 
Table 1 summarizes the different TG models discussed 
in this section.
IMMUNOTHERAPY: THE NEW 
CHALLENGE FOR MURINE MODELS
In recent years, we observed a paradigm shift in the 
treatment of different malignancies with the increasing 
introduction into the clinical practice of novel agents or 
innovative strategies aimed to improve patients’ immune 
response against cancer cells [83–89]. Specifically, 
the discovery of immune checkpoints and the rapid 
development of inhibitory monoclonal antibodies to these 
molecules raised the question on the best suitable model 
to choose for the study of new immune-modulatory 
agents. In this view, several immunocompetent mouse 
models of MM, including the 5TMM and vk*MYC, have 
been widely used to investigate the role of different 
immunosuppressive cell populations and the activity 
of checkpoints inhibitors such as anti-PD1 mAbs [90–
95]. However, further efforts are required to generate 
the “ideal” model for cancer immunotherapy, i.e. mice 
bearing a fully competent immune system able to mount 
an effective anti-cancer response [96]. The SCID-hu 
and the SCID-synth-hu represent a strong improvement 
in this direction, especially taking into account that 
immune populations, such as dendritic cells, have been 
reported to be present and functionally active in the latter 
model [97].
CONCLUDING REMARKS AND 
PERSPECTIVES
In vivo models of MM have increased the 
understanding of the disease complexity. On a historical 
point of view these models have evolved with the major 
aim of better defining the complexity of the cross-talk 
between tumor cells and their BMM and also to provide 
predictive tools for investigation of new agents. The recent 
interest in the discovery of agents capable of targeting and 
modulate regulatory networks driven by non-coding agents 
[98, 99] has further underscored the need of more reliable 
models of human MM. On these bases, selecting the right 
model for each specific pre-clinical research is an essential 
point for the successful completion of investigation. In 
general, if we recollect the different systems, it is clear 
that humanized mouse models likely represent the best 
platform for future studies. Among others, two major 
breakthrough findings have recently emerged in the 
pathogenic and therapeutic scenario of MM: the clonal 
evolution [4] and the immunotherapy [100, 101]. MM 
models that allow recapitulation of the clonal competition 
for investigation of novel biological agents as well as those 
that allow the design and evaluation of immunotherapeutic 
strategies within an appropriate microenvironment, will 
likely provide the most relevant platforms and impact in 
future translational studies on MM.
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Table 1: Transgenic murine models of MM
TG Model TG Genomic aberrations Growth Pattern
C.H2-Ld-IL6 Ld-IL-6 T(12,15);c-MYC rearrang
E.M. monoclonal plasmacytomas/B 
cell lymphomas
v-ABL Eμ-v-abl T(12,15);c-MYC rearrang E.M. monoclonal plasmacytomas
Vk*MYC V-k exon-c-MYC SHM dependent c-MYC expression in CD138+ PCs I.M. MGUS/MM
XBP-1 Eμ-xbp1 Cyclin D1; MAF upreg. I.M. MGUS/MM
c-MAF Eμ-IgH-c-MAF X-BP1, Blimp-1 upreg.; PAX-5 dowreg.
Plasmablastic/plasmacytic 
lymphomas
Bcl-B Eμ-IgH-Bcl-B IGF-1, IL-6, c-MYC, X-BP1, IRF-4 upreg. I.M. MM
IL-6 Knock in Rag2 -/- IL2R -/-/hIL-3-MCSF-GMCSF-TPO-IL-6 knock ins Parental MM cell aberrations
Recipient of MGUS/sMM/MM PCs
I.M. growth pattern
Table 1 illustrates the main TG models discussed in the text together with the most relevant genomic aberrations detected in 
TG mice and the pattern of proliferation of malignant PCs (see text for further details). Abbreviations: rearrang.: genomic 
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